GPCR vs. AGIO, EVO, GLPG, CPRX, HRMY, NAMS, SNDX, EWTX, SDGR, and SUPN
Should you be buying Structure Therapeutics stock or one of its competitors? The main competitors of Structure Therapeutics include Agios Pharmaceuticals (AGIO), Evotec (EVO), Galapagos (GLPG), Catalyst Pharmaceuticals (CPRX), Harmony Biosciences (HRMY), NewAmsterdam Pharma (NAMS), Syndax Pharmaceuticals (SNDX), Edgewise Therapeutics (EWTX), Schrödinger (SDGR), and Supernus Pharmaceuticals (SUPN). These companies are all part of the "pharmaceutical preparations" industry.
Structure Therapeutics (NASDAQ:GPCR) and Agios Pharmaceuticals (NASDAQ:AGIO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, community ranking, dividends, media sentiment and earnings.
Agios Pharmaceuticals received 463 more outperform votes than Structure Therapeutics when rated by MarketBeat users. However, 78.95% of users gave Structure Therapeutics an outperform vote while only 67.71% of users gave Agios Pharmaceuticals an outperform vote.
Structure Therapeutics has a net margin of 0.00% compared to Agios Pharmaceuticals' net margin of -1,199.26%. Structure Therapeutics' return on equity of -30.28% beat Agios Pharmaceuticals' return on equity.
Structure Therapeutics currently has a consensus target price of $85.71, suggesting a potential upside of 138.89%. Agios Pharmaceuticals has a consensus target price of $35.00, suggesting a potential upside of 0.00%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Structure Therapeutics is more favorable than Agios Pharmaceuticals.
91.8% of Structure Therapeutics shares are owned by institutional investors. 4.2% of Agios Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Structure Therapeutics has higher earnings, but lower revenue than Agios Pharmaceuticals. Structure Therapeutics is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Structure Therapeutics had 5 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 9 mentions for Structure Therapeutics and 4 mentions for Agios Pharmaceuticals. Structure Therapeutics' average media sentiment score of 1.07 beat Agios Pharmaceuticals' score of 0.63 indicating that Structure Therapeutics is being referred to more favorably in the media.
Summary
Structure Therapeutics beats Agios Pharmaceuticals on 12 of the 16 factors compared between the two stocks.
Get Structure Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GPCR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GPCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Structure Therapeutics Competitors List
Related Companies and Tools
